Article

Probiotics: preventing antibiotic-associated diarrhea.

Journal for Specialists in Pediatric Nursing (Impact Factor: 0.78). 04/2010; 15(2):160-2. DOI: 10.1111/j.1744-6155.2010.00231.x
Source: PubMed

ABSTRACT Probiotics are live microorganisms that offer a health benefit to the host. Found typically in dietary supplements, probiotics can be safely used in the treatment of acute diarrheal disease, inflammatory bowel disease, and antibiotic-associated diarrhea. They can be found in milks, yogurt, powders, and pills.
Research has shown that several strains of probiotics are helpful in the prevention and treatment of antibiotic-associated diarrhea. The most commonly studied probiotics are Lactobacillus GG and Saccharomyces boulardii.
By understanding the uses, dosages, and safety of common probiotics, nurses can help educate patients and their families on the benefits of probiotics.

0 Bookmarks
 · 
89 Views
  • Expert Review of Anticancer Therapy 04/2012; 10(4):407-9. · 3.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We investigated the efficacy of treatment with multi-species probiotics on IBS symptoms and the alterations of gut microbiota in patients who have taken probiotics. This randomized, double-blind, placebo-controlled trial involved 49 IBS patients (probiotics: 25, placebo: 24) diagnosed according to the Rome III criteria. Patients were randomly assigned to two groups: either to receive multi-species probiotics (a mixture of Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus rhamnosus, and Streptococcus thermophilus) twice a day for four weeks, or to receive a placebo twice a day for four weeks. The primary efficacy endpoint was the proportion of participants whose IBS symptoms were substantially relieved at week 4. Secondary endpoints were the intensity of abdominal pain/discomfort, bloating, stool frequency/consistency, alterations in fecal microflora over the four weeks. Fecal microflora were analyzed in 34 patients (probiotics: 17, placebo: 17) by quantitative real-time PCR assays. The proportion of patients whose IBS symptoms were substantially relieved at week 4 was significantly higher in the probiotics group than in the placebo group: 68.0% (17/25) vs. 37.5% (9/24) (p<0.05). Secondary endpoints such as improvement in abdominal pain/discomfort and bloating occurred in the probiotics group but not in the placebo group. Fecal analysis revealed that B. lactis, L. rhamnosus and S. thermophilus had increased significantly in the probiotics group after four weeks, and that B. lactis had increased in the placebo group. Multi-species probiotics are effective in IBS patients, and induced the alterations in the composition of intestinal microbiota.
    Journal of Gastroenterology and Hepatology 07/2013; · 3.33 Impact Factor

Full-text

View
0 Downloads
Available from